The guidelines mentioned in the year 2022 recommend the use of SGLT2 cotransporters in the management of hyperglycemia and decrease the mortality and morbidity related to HF in patients who suffer from T2DM and HF [13] based on EMPEROR-Reduced [14], DAPA-HF [15], and DECLARE-TIMI 58 [16]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.